Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Evaluation of the Roche Elecsys Anti-SARS-CoV-2 Assay

CS Lau, SP Hoo, SF Yew, SK Ong, LT Lum, PY Heng, JG Tan, MS Wong, TC Aw
doi: https://doi.org/10.1101/2020.06.28.20142232
CS Lau
1Department of Laboratory Medicine, Changi General Hospital, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SP Hoo
1Department of Laboratory Medicine, Changi General Hospital, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SF Yew
1Department of Laboratory Medicine, Changi General Hospital, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SK Ong
2Department of Pathology, Sengkang General Hospital, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LT Lum
2Department of Pathology, Sengkang General Hospital, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PY Heng
3Department of Laboratory Medicine, Khoo Teck Puat Hospital, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JG Tan
3Department of Laboratory Medicine, Khoo Teck Puat Hospital, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MS Wong
3Department of Laboratory Medicine, Khoo Teck Puat Hospital, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TC Aw
1Department of Laboratory Medicine, Changi General Hospital, Singapore
2Department of Pathology, Sengkang General Hospital, Singapore
4Department of Medicine, National University of Singapore, Singapore
5Academic Pathology Program, Duke-NUS Medical School, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tarchoon@gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Little is known about the performance of the Roche novel severe acute respiratory syndrome coronavirus 2 antibody (anti-SARS-CoV-2) assay. We provide an extensive evaluation of this fully automated assay on the Cobas e801/e602 immunoassay analysers.

Methods We assessed the linearity, precision, and throughput of the Roche anti-SARS-CoV-2 assay. Sensitivity was calculated from 349 SARS-CoV-2 polymerase chain reaction (PCR) positive samples; specificity was determined from 714 coronavirus disease 2019 (COVID-19)-naive samples. We examined cross-reactivity against other antibody positive samples (syphilis, RF, ANA, ds-DNA, influenza, dengue, HBV, HCV) and the anti-SARS-CoV-2 kinetics.

Results The assay cut-off index (COI) was linear up to 90.7. The inter-assay precision was 2.9% for a negative control (COI=0.1) and 5.1% for a positive control (COI=3.0). Assay time is 18min and results are available 1 minute later; throughput for 300 samples was 76 minutes. No cross-reactivity was observed with other antibody positive samples; specificity was 100%. The assay has a sensitivity of 97.1% 14 days after PCR positivity (POS) and 100% at ≥21 days POS; 48.2% of cases had anti-SARS-CoV-2 within 6 days POS. In 11 subjects in whom serum was available prior to a positive antibody signal (COI ≥1.0) the interval between the last negative and first positive COI (time to “sero-conversion”) on average is 3 days (range 1-6 days) and 4 more days (range 1-7) for the anti-SARS-CoV-2 to plateau.

Conclusion The Roche anti-SARS-CoV-2 assay shows excellent performance with minimal cross-reactivity from other viral and confounding antibodies. Antibody development and sero-conversion appears quite early.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

NA

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

CHANGI GENERAL HOSPITAL INSTITUTIONAL REVIEW BOARD

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Disclosure: All authors have nothing to disclose.

Data Availability

NA

  • ABBREVIATIONS

    SARS-CoV-2
    Novel severe acute respiratory syndrome coronavirus 2
    COVID-19
    Coronavirus disease 2019
    Anti-SARS-CoV-2
    SARS-CoV-2 antibody
    FDA
    Food and Drug Administration
    HCV
    Hepatitis C
    HBV
    Hepatitis B
    RF
    Rheumatoid factor
    HCWs
    Health care workers
    COI
    Cut-off index
    PCR
    Polymerase chain reaction
    CV
    Inter-assay precision
    PPA
    Positive percentage agreement
    NPA
    Negative percentage agreement
    POS
    Post positive PCR
    PPV
    Positive predictive value
    NPV
    Negative predictive value
    CDC
    Centers for Disease Control and Prevention
    PPE
    Personal protective equipment
    ANA
    anti-nuclear antibody
    Anti-ds-DNA
    double-stranded DNA antibody
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted June 29, 2020.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Evaluation of the Roche Elecsys Anti-SARS-CoV-2 Assay
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Evaluation of the Roche Elecsys Anti-SARS-CoV-2 Assay
    CS Lau, SP Hoo, SF Yew, SK Ong, LT Lum, PY Heng, JG Tan, MS Wong, TC Aw
    medRxiv 2020.06.28.20142232; doi: https://doi.org/10.1101/2020.06.28.20142232
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    Evaluation of the Roche Elecsys Anti-SARS-CoV-2 Assay
    CS Lau, SP Hoo, SF Yew, SK Ong, LT Lum, PY Heng, JG Tan, MS Wong, TC Aw
    medRxiv 2020.06.28.20142232; doi: https://doi.org/10.1101/2020.06.28.20142232

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (215)
    • Allergy and Immunology (495)
    • Anesthesia (106)
    • Cardiovascular Medicine (1093)
    • Dentistry and Oral Medicine (195)
    • Dermatology (141)
    • Emergency Medicine (274)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (499)
    • Epidemiology (9757)
    • Forensic Medicine (5)
    • Gastroenterology (480)
    • Genetic and Genomic Medicine (2303)
    • Geriatric Medicine (221)
    • Health Economics (462)
    • Health Informatics (1553)
    • Health Policy (732)
    • Health Systems and Quality Improvement (602)
    • Hematology (236)
    • HIV/AIDS (501)
    • Infectious Diseases (except HIV/AIDS) (11631)
    • Intensive Care and Critical Care Medicine (616)
    • Medical Education (236)
    • Medical Ethics (67)
    • Nephrology (256)
    • Neurology (2139)
    • Nursing (134)
    • Nutrition (335)
    • Obstetrics and Gynecology (426)
    • Occupational and Environmental Health (517)
    • Oncology (1172)
    • Ophthalmology (363)
    • Orthopedics (128)
    • Otolaryngology (220)
    • Pain Medicine (145)
    • Palliative Medicine (50)
    • Pathology (309)
    • Pediatrics (694)
    • Pharmacology and Therapeutics (298)
    • Primary Care Research (265)
    • Psychiatry and Clinical Psychology (2172)
    • Public and Global Health (4645)
    • Radiology and Imaging (775)
    • Rehabilitation Medicine and Physical Therapy (455)
    • Respiratory Medicine (623)
    • Rheumatology (274)
    • Sexual and Reproductive Health (225)
    • Sports Medicine (208)
    • Surgery (250)
    • Toxicology (43)
    • Transplantation (120)
    • Urology (94)